Our Goal is to deliver
an asset, ready for scaling up for pilot
and GLP safety studies, with a strong pre-clinical beneficial therapeutic effect
link

$20m (pre)seed
investment vehicle

for early stage syndicated investments in biotech companies in Israel
link

Focus

  • Initial review criteria
  • Area’s of interest
  • Stage of opportunity

link

ExploreBio1

Positioned to be key player
in T-cell engager space
Read more

PANTHEON BIOSCIENCE

Positioned to disrupt the
molecular tools space
Read more